outlines the design, development, implementation, and evaluation of adapted regimens and specifies 54 levels of services needed to deliver them. 55
Introduction 56 57

Need for adapted regimens for use in low-and middle-income countries (LMIC) 58
Many pediatric cancer units (PCUs) in low-and middle-income countries (LMIC) treat children 59 with cancer, but lack the infrastructure available to PCUs in high-income countries (HIC). Treatment 60 using standardized regimens or protocols has led to unprecedented improvements in survival of children 61 with cancer, but most published regimens are based on therapies developed and delivered in HIC. 62
Treatment outcomes with these regimens differ in PCUs that treat different patient populations and lack a 63 full complement of diagnostic facilities, imaging modalities, treatment components, and supportive care. 1 
64
Accordingly, treatment risks and benefits may differ substantially between LMIC and HIC. 65
For example, the Total XI protocol for childhood acute lymphoblastic leukemia (ALL) achieved a 66 72% event-free survival (EFS) in the United States, but when implemented in Recife, Brazil, the EFS was 67 32%. 2, 3 The same regimen was used in El Salvador with adaptations designed to reduce toxicity, including 68 a 3-drug induction without anthracyclines. 4 This approach increased 4-year EFS from less than 10% to 69 48%. However, despite these adaptations, the rate of toxic death was 12.4% during remission induction 70 therapy and another 4.6% in remission. This emphasizes the need to not only adapt treatment for LMIC, 71 but also to carefully evaluate the results of adapted regimens to identify opportunities for further 72 improvement. 5 
73
The first adapted regimens developed were called "graduated intensity regimens," a term replaced 74 by "adapted treatment regimens" because the necessary adaptations often do not involve changes in 75 chemotherapy intensity, but also incorporate use of distinct methods of staging, risk stratification, local 76 control, and supportive care. 6 For example, the retinoblastoma guidelines applied this adaptation process 77 to outline treatment based on availability of specific ophthalmologic interventions. 7 Similarly, additional 78 chemotherapy was used for Wilms tumor and Hodgkin lymphoma when radiation therapy is 79 unavailable. 8, 9 Adaptations may include major changes in therapy, such as addition of chemotherapy and 80 omission of radiation therapy in Wilms tumor, but could also include relatively minor alterations, such as 81 omission of 2 doses of doxorubicin from acute lymphoblastic leukemia remission induction therapy or 82 use of prophylactic antibiotics when the risk/benefit ratio differs in LMIC and HIC. 83
It might be tempting to defer childhood cancer treatment in settings with suboptimal 84 infrastructure, but this would be unwise, since most children have no option for transfer to a more 85 advanced PCU, and many are curable even in settings with limited resources. For example, Burkitt 86 lymphoma in African PCUs has been successfully treated with reduced-intensity regimens, despite very 87 limited supportive care and related infrastructure. [10] [11] [12] Indeed, treatment with a high-intensity regimen 88 when supportive care is inadequate can lead to paradoxically lower EFS by increasing toxic death more 89 than it decreases relapse. [13] [14] [15] [16] Cure rates can rise quickly with focus on preventing treatment abandonment, 90 reducing toxic death, and adapting the diagnostic strategy, risk stratification algorithm, and treatment 91 regimen to the local situation. 4 In Recife, Brazil, the cure rates for childhood ALL increased from 32% to 92 over 65% using adapted regimens accompanied by rigorous programs to prevent treatment abandonment 93 and reduce toxic death. 3, 17 Curing the curable is ethically mandatory and highly cost-effective even in 94 LMIC. [18] [19] [20] 
96
Obstacles to adapting treatment regimens 97
Obstacles to adapting treatment regimens to local conditions have included an unwillingness to 98 deviate from published regimens used in HIC due to provider preferences, cultural or historical reasons, 99 misperception that 'more is better,' lack of published evidence about adapted regimens, insufficient local 100 data on which to base rational adaptations (due to lack of hospital-based registries and routine outcome 101 evaluation of locally treated patients), perceived ethical concerns about using a less intense regimen, and 102 lack of time and expertise by LMIC physicians to adapt each regimen to local conditions. In some cases, 103 physicians practicing in LMIC care for 10 times more patients than their counterparts in HIC. This makes 104 it very challenging for them to engage in activities other than direct patient care, even if those activities 105 might ultimately improve survival in their PCU. Furthermore, conditions in PCUs vary greatly, even 106 within the same country. While there is general agreement that patients should be treated at the PCU thatoffers the highest chance of cure, many LMIC have heterogeneous levels of care at various centers 108 combined with complex health systems that may mandate treatment at a specific PCU based on insurance 109 coverage and other factors unrelated to expertise. 110 111
Development and implementation of adapted treatment regimens 112
Several strategies have been employed to overcome the aforementioned obstacles (Table 1) . 113
Many clinicians have devised strategies to try to cure as many patients as possible despite the lack of key 114 infrastructure at their center. For example, treatment of Hodgkin lymphoma and Wilms tumor without 115 radiation therapy was first considered in PCUs without access to radiation therapy, and use of reduced 116 doses of high-dose methotrexate in ALL and non-Hodgkin lymphoma regimens has been studied 117 extensively in LMIC. 9, [21] [22] [23] [24] In fact, these and other innovative strategies now used in HIC to minimize 118 toxicity and optimize long-term outcomes were pioneered in LMIC to address conditions that made the 119 HIC regimen impractical in the local setting, including retinoblastoma staging, treatment of osteosarcoma 120 without high-dose methotrexate, and others. 25, 26 
121
To develop and disseminate adapted treatment strategies, the Pediatric Oncology in Developing 122
Countries (PODC) Committee of the International Society of Pediatric Oncology (SIOP) established the 123
Adapted Treatment Regimens Working Group, charged with providing such regimens for use in LMIC. 30 
124
The volunteer leaders serve for 3-year terms and volunteer members carry out the projects. Meetings are 125 conducted online via www.Cure4Kids.org and members listed on the SIOP web site (www.siop-126 online.org). To date, working group members have published adapted regimens for 7 cancers along with 2 127 supportive care manuscripts. [5] [6] [7] [27] [28] [29] [30] [31] [32] [33] [34] The published adapted regimens were developed with broad input 128 from clinicians in multiple disciplines, and experts from LMIC and HIC, and have been improved during 129 extensive review by peers from the global oncology community. Where possible, recommendations have 130 been evidence-based, but when published evidence to guide regimen selection was not available, as is 131 often the case in the most resource-limited settings, expert opinion was used. Four of these guidelines 132 (Wilms tumor, Kaposi sarcoma, Burkitt lymphoma, and supportive care [35] [36] [37] ) were designed for settings in 133 low-income countries where only the minimal requirements for treatment with curative intent are 134 available (defined as setting 1, see Table 2 ). However, for some cancers, definition of an overall level of 135 care was insufficient to select the best treatment regimen, because they depend on access to a particular 136 component of care, such as neurosurgery for brain cancers or radiation therapy for unresectable sarcomas. 137 Therefore, a framework based on specific service lines was required to guide clinicians to the best 138 treatment, and to highlight the need for certain service lines to treat specific cancers. This paper provides 139 such a framework and suggests components for each adapted regimen to make it maximally useful and 140
applicable. 141 142
Choosing the optimal therapy depends on the setting 143
The "optimal" therapy in LMIC is not necessarily that used in HIC, but that which provides each 144 child with the highest probability of cure in the given setting at the time of diagnosis. Of necessity, in 145 LMIC the optimal therapy will change over time, with improvements in diagnostic accuracy, surgical 146 expertise, improved access to supportive care and treatments such as radiation therapy or new drugs, 147 implementation of treatment abandonment prevention programs, and as improved regimens are identified 148 by research in HIC and LMIC. If the relapse rate with a given therapy is excessive, then the treatment 149 may need intensification; however, if toxic death rates are too high, de-intensification may save more 150 lives, pending improvements in supportive care. Therefore, constant evaluation of the regimens is 151
imperative. 152
Selection of the optimal regimen for patients treated in a specific setting does not preclude 153 making every effort to improve the environment of care. Explicit identification of the care that can be 154 safely delivered may help prioritize quality improvement efforts. In general, priorities to improve survival 155 rates include investments in core services for appropriate diagnosis and management: pathology and 156 diagnostic imaging; nursing and access to essential medicines; prevention of toxic death by hand hygiene 157 programs and rapid access to effective antibiotics; prevention of abandonment by provision of subsidized 158 transportation, local housing, and food baskets; and family education and support programs. However, 159 after these essentials are in place, whether efforts should be put toward early diagnosis of retinoblastoma, 160 local control for sarcoma patients, development of neurosurgical expertise for brain tumors, improved 161 diagnosis and risk stratification systems, or other important aspects of pediatric cancer care depends on 162 many factors. Of course, the initial focus should always be on curing the most curable patients. While the 163 choice of focus and resource allocation will differ in different centers, prioritization can be evidence-164 based once incidence and outcome data are available for the various cancer types treated with adapted 165 regimens and explicit evaluation criteria are formulated for each. For example, a PCU in which 20% of 166 children with ALL die of toxicity during the first 3 months of therapy would appropriately select the 167 Level 1 regimen for ALL, but as supportive care improves and toxic death decreases to 3%, excess 168 relapse with a low-intensity treatment regimen may merit stepping up to the Level 2 regimen (Table 2) . This framework document facilitates the adaptation process, standardizes terminology and levels 204 of care, and assures that all necessary elements are included in each published adapted regimen. We hope 205 that this will be followed by a proliferation of regimens adapted to various situations and prospectively 206 validated in research studies. In this regard, the Wilms tumor regimen for Level 1 settings is being studied 207 by a group of 8 centers in sub-Saharan Africa, which will show how the adapted regimen and its 208 implementation can be further improved. tumor an adapted chemotherapy-only regimen is warranted. 38, 39 The selection of the initial treatment 219 regimen for each disease should be based on levels of service relevant to the disease and available to the 220 patient, not on the overall level of the PCU. Service levels for this framework paper were developed by a 221 consensus of working group members in consultation with domain experts from HIC and LMIC (e.g. 222 radiologists for radiology section, surgeons for surgery section). These represent a starting point for 223 definition of service levels, which require significantly more nuanced and disease-specific definition and 224 validation. For example, management of Hodgkin lymphoma generally does not require MRI, so one 225 could consider availability of Level 3 diagnostic imaging services for Hodgkin lymphoma even if the 226 center lacks access to MRI. However, for sarcomas, a hospital lacking MRI would be considered Level 2. 227
Ultimately, we envision using this framework to help writing groups created service levels that are 228 disease-specific and to some extent protocol-specific. 229
Service levels outlined here are not primarily meant to be used to evaluate PCUs; rather, to help 230 clinicians best choose the starting level for each disease (from which they will "step up" or "step down" 231 as indicated by the stopping rules in each adapted regimen based on toxic death and relapse rates). 232
Nuanced definition of service lines and application to adapted regimens for specific cancers will be 233 carried out by global strategy groups like the World Health Organization, commissioned strategy groups 234 like the Lancet Commissions, SIOP PODC Working Groups, regional networks, and others. 235
Assessment of levels of care by service line and the importance of effective access 237
This paper does not purport to offer a detailed guide to assessment and classification of PCUs; 238 however, assessment of the level of each service line relevant for each cancer is a necessary first step to 239 select the appropriate treatment regimens that will optimize outcomes. It must be emphasized that the 240 level of each service line should reflect the level of service to which most patients have "effective 241 access." The existence of services is irrelevant if the patient cannot access them due to overcrowding or 242 inability to pay. A hospital with a Level 3 intensive care unit that is always full and therefore does not 243 accept oncology patients is considered to have Level 0 intensive care, and the regimens adapted 244 accordingly. Using an intense regimen that requires intensive care is a mistake at this hospital, since 245 effective access influences toxic death rates. When determining the levels of service lines available, 246
clinicians are encouraged to think in narrow terms: what services are effectively available to most patients 247
most of the time? 248
Supportive care is important in the management of all pediatric cancers, but the level needed for 249 acute myeloid leukemia (Level 3 for services including blood bank, intensive care, infection prevention 250 and control) is higher than that needed for low-stage Wilms tumor (Level 0 or 1). Nutritional support is 251 particularly important in LMIC, where malnutrition at diagnosis or during treatment is prevalent, and can 252 increase the complication rate even for therapies that had minimal toxicity in HIC. [40] [41] [42] [43] The PODC 253
Adapted Treatment Regimens Working Group Guidance for supportive care in LMIC has published 254 guidance for LMIC, and many HIC guidelines are relevant for LMIC. 28, 44 All PCUs should have a 255 multidisciplinary team, regardless of resource constraints. A team of doctors from multiple specialties, 256 nurses, social workers, pharmacists, and data managers can accomplish most when working together. This 257 core team can later mobilize other key professionals and community advocates needed for cancer care. Review by Working Group members and approval by group leaders is mandatory for all adapted 271 regimens prior to submission to the SIOP Publications Committee to assure that all criteria are met and 272 that the final product is clear and practical. Once approved, the manuscript may be submitted for 273 additional peer review and publication. All manuscripts describing SIOP PODC adapted regimens should 274 conform to the requirements enumerated in Table 3 . Adapted regimens are designed with curative intent, 275
even if conditions at the PCU suggest a regimen with a cure rate known to be less than that achievable in 276 HIC. Use of the adapted regimen is ethically supported by the fact that alternative regimens, or lack 277 thereof, would result in even lower cure rates. However, if a patient has access to a PCU with a higher 278 cure rate for their disease, referral to that center is ethically mandatory. Furthermore, if patients have 279 access to a locally adapted clinical trial this would be preferred over an adapted treatment regimen, which 280 purports to describe the best standard therapy available for a given patient in a specific setting. However, 281 awaiting the development and funding for such a clinical trial before implementing the best standard local 282 care possible is not acceptable. Clinicians must attempt to choose the best treatment for each new patient 283 each day, and adapted regimens are designed to facilitate this choice while awaiting better evidence (and 284 better services within the PCU) to cure even more patients in the future. 285 286
Adapted regimen dissemination, field testing, and updates 287
The dissemination strategy has several components, including publication, presentation at SIOP 288
Annual Meetings, regular open meetings of the SIOP PODC Adapted Treatment Regimen Working 289
Group, education sessions via www.Cure4Kids.org, and creation of a repository of adapted regimens 290 available via the SIOP web page and Cure4Kids. Extension of the concepts by Childhood Cancer 291
International, consortia like GFAOP and AHOPCA, and groups like the Lancet Oncology Commission 292 will provide further visibility. Getting the first set of adapted treatment regimens into the public sphere 293 was the first priority of the SIOP PODC Adapted Treatment Regimen Working Group, because as 294
Loblaw et al. point out: "…it is often the areas of greatest uncertainty in which the evidentiary base is 295 incomplete, and thus, guidelines are needed most." 45 
296
The initial group of adapted regimens were developed using a series of consensus meetings held via 297 regular online meetings by disease-specific working groups with feedback from the larger Working 298
Group that includes all members of the disease-specific working groups. After the first step (creation of 299 the adapted regimen), the critical next steps include 1) prospective validation in a variety of centers that 300 use the adapted regimen, 2) evaluation of practical implementation barriers, and 3) documentation of 301 patient outcomes. This process is ongoing for acute lymphoblastic leukemia and Wilms tumor, and will 302 be followed by revision of the adapted treatment regimen to address implementation barriers and modify 303 the regimen as necessary based on results plus any new published relevant literature from HIC or LMIC. 304
The Working Group should review each adapted treatment regimen annually and update it every 3 years. 305 306
Selection of the optimal regimens for the Pediatric Cancer Unit 307
The "optimal" treatment regimen depends on rates of treatment failure, toxic death, abandonment, 308 second cancer, and the salvage rate for those who relapse. Ideally, treatment regimens best suited to each 309 site would be established in collaboration with local clinicians, national, and international disease experts. 310
The adapted regimen anticipated to cure the highest number of patients given the current status of the 311 PCU should be used. It may be more intense, less intense, or simply different (such as using additional 312 chemotherapy when radiation therapy is not available) than regimens used in HIC.radiation therapy were documented in the short term (5-10 years) for various subgroups of patients. In the 315 CCG5942 trial, patients with complete remission after chemotherapy were randomized to no further 316 therapy or involved-field radiation therapy. 46 At 10 years, EFS of children who received radiation therapy 317 was 8% higher than with chemotherapy alone, but overall survival was similar. 47 However, as late effects 318 of radiation therapy occur longer than 10 years after treatment, in the long-term, omission of radiation 319 therapy actually predicted better outcomes (in HIC). Indeed, a recently published decision analysis of 320 patients treated in HIC found that average conditional life expectancy was higher without radiation 321 therapy (57.2 years versus 56.4 years). 48 However, this model does not apply in LMIC, where the rates of 322 successful salvage therapy for those who relapse may be much lower than in HIC. 49 In settings where 323 salvage therapy is suboptimal, and few survivors are seen following relapse, a more intense front-line 324 regimen may be preferred, and the benefits of radiation therapy may be greater than they were in HIC. 325
Thorough evaluation of the level of each service line, combined with prospective analysis of 326 outcomes for patients treated previously to document rates of abandonment, toxic death, relapse, and 327 successful salvage allows selection of an appropriate approach for each cancer that will cure the greatest 328 number of patients at each PCU. Service lines provide a framework for initial selection of the adapted 329 regimen likely to have the highest cure rate in the specific setting, but the regimen may need adjustment 330 based on outcome evaluation in case the initial selection was not optimal. Furthermore, regimens should 331 be periodically evaluated and adjusted based on changing conditions: if the PCU improves access to 332 intensive care for cancer patients, adds a guest house for patients who live far away, increases the number 333 of nurses, or improves the speed with which antibiotics can be administered to patients with febrile 334 neutropenia, then the best adapted regimen for some diseases may change. 335
336
Individualized treatment for specific patients 337
Individualized management of specific patients, whether on an adapted regimen or not, is inevitable in 338 oncology. Such individualized management depends on the experience of the treating clinician, ideally 339 complemented by local multidisciplinary tumor boards and consultation with national or international 340 disease experts. Although beyond the scope of this paper, the guiding principle for individualized 341 management is to maximize the probability of cure for each individual patient. Use the service lines and levels outlined in this guidance paper ( Table 2 ). The writing committee for each adapted regimen is expected to elaborate where necessary. Diagnosis and risk stratification Specify the approach to the disease-specific elements needed for adapted diagnosis, staging, and risk stratification Include a flow chart with a clear algorithm to guide application of the adapted diagnosis, staging, and risk stratification to arrive at the correct adapted treatment regimen (see the example in Figure 3 ).
Treatment regimens
Identify the levels of each service line needed for each level of the adapted regimen (see the example in Figure 2 ). Specify adapted treatment regimens and response evaluation in a table with details sufficient to treat the patient (number of cycles, criteria to start each cycle, required and recommended monitoring, dose modification recommendations for toxicities, timing of local control when relevant, timing of response evaluation, response criteria). Include alternatives with similar efficacy where they exist (e.g. ABVD vs. OEPA/COPDac for Hodgkin lymphoma). Outline key management differences for initial regimen selection and any alteration in timing of surgery or chemotherapy as mandated by local surgical or patient factors (e.g. upfront surgery vs. chemotherapy for retinoblastoma or Wilms tumor). Provide detailed recommendations and rationale to guide potential decision-making for chemotherapy substitution or regimen readjustments when individual chemotherapeutic agents are missing. Provide treatment roadmaps that include all elements of treatment for all phases of the regimen (drugs, doses, route of administration, fluid in which to mix the chemotherapy, schedule, recommended evaluations, timing of local control). Explicitly recommend strategies to treat patients when key elements are missing (e.g. lack of radiation therapy, laser therapy for local control of retinoblastoma, or access to stem cell transplantation). Make the adapted regimens as evidence-based as possible and provide supporting references.
Evidenced-based recommendations
Note the level of evidence available for specific recommendations, and outline to the extent possible the practice settings where evidence has been primarily generated. Supportive care
Provide supportive care recommendations that address common toxicities of the proposed regimens and any unique complications of the cancer. No need to provide general recommendations, which are available from various sources. 23 
Diagnostic evaluation and monitoring
Consider any data that may support less intense diagnostic evaluation or monitoring. Consider evidence that justifies allocation of resources for specific testing. Selection of the most appropriate initial regimen for a particular pediatric cancer unit Provide guidance to help clinicians identify the optimal regimen for their patients given the available resources. Include stopping rules for toxic death when one should "step down" to a less intense regiment. Provide criteria to "step up" to the next regimen and specific guidance about when and how to step up or step down to a different regimen to cure the highest number of children possible.
Review process
Follow the approval process that includes review by the SIOP PODC Adapted Treatment Regimens Working Group leaders and by the SIOP Publications Committee prior to submission for publication (See Figure 1) 
